New cocktail of drugs targets Hard-to-Treat bile duct cancer
NCT ID NCT07159217
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests a combination of three drugs—disitamab vedotin, lenvatinib, and a PD-1 inhibitor—for people with HER2-positive advanced biliary tract cancer that cannot be removed by surgery. The study will enroll 65 participants to see how well the treatment shrinks tumors and controls the disease. Researchers will also monitor side effects closely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
disitamab vedotin, lenvatinib, and a PD-1 inhibitor (pembrolizumab, toripalimab, or camrelizumab)
What this could lead to
If successful, this could point toward a new treatment option for people with HER2-positive advanced biliary tract cancer, potentially shrinking tumors and extending life.
What could go wrong
This is an early phase 2 trial with only 65 participants and no comparison group, so results may not be definitive. The combination of three drugs may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact